1-Propanaminium, 2,3-dihydroxy-N,N,N-trimethyl- | 44814-66-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Propanaminium, 2,3-dihydroxy-N,N,N-trimethyl-
• 英文别名: 2,3-dihydroxypropyl(trimethyl)azanium
• CAS: 44814-66-6
• 化学式: C6H16NO2+
• 分子量: 134.2
• InChiKey: SVMYVYPFRUNJLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• PERSONAL CARE COMPOSITIONS CONTAINING QUATERNARY AMMONIUM TRIHYDROXY SUBSTITUTED DIPROPYL ETHER
  申请人：Harichian Bijan

  公开号：US20070212324A1

  公开（公告）日：2007-09-13

  A personal care composition is provided which includes a trihydroxy and quaternary ammonium substituted dipropyl ether. The substituted dipropyl ether functions as a humectant when applied to human skin to moisturize both in high and low relative humidity environments.

  提供了一种个人护理组合物，其中包括三羟基和季铵取代的二丙基醚。当应用于人体皮肤时，取代的二丙基醚作为保湿剂，在高湿度和低湿度环境下都能起到保湿作用。
• Quaternary ammonium polyol salts as anti-aging actives in personal care compositions
  申请人：Harding Roderick Clive

  公开号：US20060089277A1

  公开（公告）日：2006-04-27

  A personal care product is provided which includes a package filed with a personal care composition and instructions printed on or associated with the package indicating topical use of the composition on skin for purposes of controlling the signs of aging. The composition includes a quaternary ammonium compound selected from (a) salts of hydroxypropyltri(C 1 -C 3 alkyl)ammonium mono-substituted mono-saccharide; (b) salts of hydroxypropyltri(C 1 -C 3 alkyl)ammonium mono-substituted polyols, the salts having a cation of an average molecular weight no higher than about 450 and the salt having a T g no higher than about 10° C.; (c) dihydroxypropyltri(C 1 -C 3 alkyl)ammonium salts; (d) chlorohydroxypropyltri(C 1 -C 3 alkyl)ammonium salts; and (e) mixtures thereof.

  提供了一种个人护理产品，其中包装填充有个人护理成分，并在包装上或与之相关的说明中打印有指示在皮肤上局部使用该成分以控制老化迹象的说明。该组成物包括从以下选择的季铵化合物：（a）羟丙基三（C1-C3烷基）铵单取代单糖盐；（b）羟丙基三（C1-C3烷基）铵单取代多元醇盐，所述盐具有平均分子量不高于约450的阳离子，盐具有Tg不高于约10°C；（c）二羟丙基三（C1-C3烷基）铵盐；（d）氯羟丙基三（C1-C3烷基）铵盐；以及（e）其混合物。
• Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
  申请人：——

  公开号：US20040219202A1

  公开（公告）日：2004-11-04

  The present invention provides a composition comprising (i) a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein the non-polar moiety is of the formula X-Y-Z- wherein X is an acetylenic hydrocarbyl group containing a single C≡C bond, Y is O or CH 2 , and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula -[T] m PHG, wherein [T] m is an optional group selected from C(O), NH, NR 1 , NHC(O), C(O)NH, NRIC(O) and C(O)NR 1 and CH 2 , where R 1 is a hydrocarbyl group, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties (ii) a therapeutic agent.

  本发明提供了一种组合物，包括（i）脂质化合物，其包括至少一个非极性基团和一个极性基团，其中非极性基团的化学式为X-Y-Z-，其中X是含有单个C≡C键的乙炔基烃基团，Y是O或CH2，Z是可选的烃基团，极性基团的化学式为-[T] m PHG，其中[T] m是可选的基团，选自C（O）、NH、NR1、NHC（O）、C（O）NH、NRIC（O）和C（O）NR1和CH2，其中R1是烃基团，PHG是极性头基团，m是非极性基团的数量；（ii）一种治疗剂。
• Novel benzothiazepine and bensothiepine compounds
  申请人：Sasahara Takehiko

  公开号：US20070190041A1

  公开（公告）日：2007-08-16

  A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive agent for obesity, fatty liver and steatohepatitis are provided. A benzothiazepine or benzothiepine compound represented by the following formula (1A) having a thioamide bond and a quaternary ammonium substitutent:

  提供了一种药物，可用作治疗和预防高脂血症的治疗剂和预防剂，以及一种药物，可用作治疗和预防与胆汁淤积有关的肝脏疾病，特别是原发性胆汁性肝硬化和原发性硬化性胆管炎的治疗剂和预防剂，以及一种药物，可用作治疗和预防肥胖症、脂肪肝和脂肪性肝炎的治疗剂和预防剂。化合物的苯并噻吩或苯并噻环代表如下式（1A），具有硫酰胺键和季铵取代基：
• Novel quaternary ammonium compounds
  申请人：Sasahara Takehiko

  公开号：US20070203115A1

  公开（公告）日：2007-08-30

  A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1):

  一种抑制回肠胆汁酸转运蛋白活性的方法，包括向该受试者施用一种由式（1）所代表的化合物的有效量：